Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer(Figure presented.)

William S. Chen, Rahul Aggarwal, Li Zhang, Shuang G. Zhao, George V. Thomas, Tomasz M. Beer, David A. Quigley, Adam Foye, Denise Playdle, Jiaoti Huang, Paul Lloyd, Eric Lu, Duanchen Sun, Xiangnan Guan, Matthew Rettig, Martin Gleave, Christopher P. Evans, Jack Youngren, Lawrence True, Primo LaraVishal Kothari, Zheng Xia, Kim N. Chi, Robert E. Reiter, Christopher A. Maher, Felix Y. Feng, Eric J. Small*, Joshi J. Alumkal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


Background: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease. Several recent studies have identified genomic alterations in mCRPC, but the clinical implications of these genomic alterations have not been fully elucidated. Objective: To use whole-genome sequencing (WGS) to assess the association between key driver gene alterations and overall survival (OS), and to use whole-transcriptome RNA sequencing to identify genomic drivers of enzalutamide resistance. Design, setting, and participants: We performed survival analyses and gene set enrichment analysis (GSEA) on WGS and RNA sequencing results for a cohort of 101 mCRPC patients. Outcome measurements and statistical analysis: OS was the clinical endpoint for all univariate and multivariable survival analyses. Candidate drivers of enzalutamide resistance were identified in an unbiased manner, and mutations of the top candidate were further assessed for enrichment among enzalutamide-resistant patients using Fisher's exact test. Results and limitations: Harboring two DNA alterations in RB1 was independently predictive of poor OS (median 14.1 vs 42.0 mo; p = 0.007) for men with mCRPC. GSEA identified the Wnt/β-catenin pathway as the top differentially modulated pathway among enzalutamide-resistant patients. Furthermore, β-catenin mutations were exclusive to enzalutamide-resistant patients (p = 0.01) and independently predictive of poor OS (median 13.6 vs 41.7 mo; p = 0.025). Conclusions: The presence of two RB1 DNA alterations identified in our WGS analysis was independently associated with poor OS among men with mCRPC. The Wnt/β-catenin pathway plays an important role in enzalutamide resistance, with differential pathway expression and enrichment of β-catenin mutations in enzalutamide-resistant patients. Moreover, β-catenin mutations were predictive of poor OS in our cohort. Patient summary: We observed a correlation between genomic findings for biopsy samples from metastases from men with metastatic castration-resistant prostate cancer (mCRPC) and clinical outcomes. This work sheds new light on clinically relevant genomic alterations in mCRPC and provides a roadmap for the development of new personalized treatment regimens in mCRPC.

Original languageEnglish (US)
Pages (from-to)562-571
Number of pages10
JournalEuropean urology
Issue number5
StatePublished - Nov 2019


  • Advanced prostate cancer
  • Castration-resistant
  • Clinical outcomes
  • Enzalutamide
  • Genomics
  • Metastatic prostate cancer
  • Prognostic factors

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer(Figure presented.)'. Together they form a unique fingerprint.

Cite this